Dr. Reddy’s launches integrated care plan to manage irritable bowel syndrome
Around 7% of the Indian population suffers from IBS
Around 7% of the Indian population suffers from IBS
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Under the arrangement, Dr. Reddy's will have exclusive rights to promote and distribute Sanofi's vaccine brands Hexaxim, Pentaxim, Tetraxim, Menactra, FluQuadri, Adacel and Avaxim 80U
Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
This investment will be made by Caplin Point Laboratories Limited and its subsidiaries - Caplin Steriles Limited and Caplin One Labs Limited
10+ emerging markets, Japan & ANZ transition in final phase
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
Subscribe To Our Newsletter & Stay Updated